90Y-ibritumomab-tiuxetan as a therapeutic alternative for follicular lymphoma (FL): A single-center experience-Reference-Cited by-同舟云学术

90Y-ibritumomab-tiuxetan as a therapeutic alternative for follicular lymphoma (FL): A single-center experience

Published:2018-09-03 Issue:4 Volume:101 Page:514-521
ISSN:0902-4441
Container-title:European Journal of Haematology
language:en
Short-container-title:Eur J Haematol

Author:

Spukti Eva U.¹^ORCID,Schmidt Lars Henning¹,Schulze Arik¹,Schliemann Christoph¹,Görlich Dennis²,Wardelmann Eva³,Hartmann Wolfgang³,Lenz Georg¹,Berdel Wolfgang E.¹,Kerkhoff Andrea¹

Affiliation:

1. Department of Medicine A, Hematology, Oncology and Pulmonary Medicine; University Hospital Muenster; Muenster Germany

2. Institute of Biostatistics and Clinical Research; Westfaelische Wilhelms-Universitaet Muenster; Muenster Germany

3. Gerhard-Domagk-Institute of Pathology; University Hospital Muenster; Muenster Germany

Funder

Deutsche Forschungsgemeinschaft

Publisher

Wiley

Subject

Hematology,General Medicine

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/ejh.13138/fullpdf

Reference46 articles.

1. Follicular lymphoma international prognostic index;Solal-Celigny;Blood,2004

2. Examination of the follicular lymphoma international prognostic index (FLIPI) in the National LymphoCare study (NLCS): a prospective US patient cohort treated predominantly in community practices;Nooka;Ann Oncol,2013

3. American Cancer Society Survival rates and factors that affect prognosis (outlook) for non-hodgkin lymphoma 2017

4. Follicular lymphoma in the United States: first report of the national lymphocare study;Friedberg;J Clin Oncol,2009

5. Follicular lymphoma, survival, and rituximab: is it time to declare victory?;Horning;J Clin Oncol,2008

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Results of a Phase II Trial of Allogeneic Hematopoietic Stem Cell Transplantation Using 90Y-Ibritumomab Tiuxetan (Zevalin) in Combination With Fludarabine and Melphalan in Patients With High-Risk B-Cell Non-Hodgkin's Lymphoma;Clinical Lymphoma Myeloma and Leukemia;2023-09

2. Monoclonal antibody based radiopharmaceuticals for imaging and therapy;Current Problems in Cancer;2021-10

3. Yttrium-90 ibritumomab tiuxetan consolidation versus rituximab maintenance therapy after induction chemotherapy in patients with indolent non-Hodgkin lymphoma: a single-institution experience;Hematology;2019-01-01